Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Sickle cell disease: an invisible illness with very real consequences
Often invisible from the outside, sickle cell disease remains one of the most common genetic disorders in France, affecting around 30.000 people. Behind this apparent invisibility lies a chronic condition that can deeply impact daily life.
This disease is caused by a genetic abnormality of hemoglobin, leading to the deformation of some red blood cells. Less flexible, these cells struggle to circulate through small blood vessels, causing pain crises, chronic anemia, and sometimes severe organ complications.
Treatment options are diverse: symptomatic care, prevention of complications, transfusions, and today, the development of gene therapies offering real hope for curative treatment.
Among the most effective approaches, red blood exchange by apheresis makes it possible to remove altered red blood cells and replace them with healthy donor red blood cells. This technique reduces blood viscosity, limits iron overload, and helps space out treatment sessions.
Beyond every protocol, there is one simple goal: helping patients live more freely.”

Other posts featuring Maxime Dely on Hemostasis Today.
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation